Drug Information

Drug General Information
Drug ID
D0W1OA
Former ID
DIB008685
Drug Name
BEMA buprenorphine transmucosal
Indication Migraine [ICD9: 346; ICD10:G43] Phase 2 [522729]
Company
Biodelivery sciences international
Target and Pathway
Target(s) Mu-type opioid receptor Target Info Agonist [526050]
KEGG Pathway Neuroactive ligand-receptor interaction
Estrogen signaling pathway
Morphine addiction
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Enkephalin release
Pathway Interaction Database IL4-mediated signaling events
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways TCR Signaling Pathway
GPCRs, Class A Rhodopsin-like
Peptide GPCRs
Opioid Signalling
GPCR ligand binding
GPCR downstream signaling
References
Ref 522729ClinicalTrials.gov (NCT00941304) Study of BEMA Buprenorphine in the Treatment of Dental Pain. U.S. National Institutes of Health.
Ref 526050Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.